Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PBT2 effect on Caffeine PK in healthy volunteers
NCT02109497Phase 1Completed
- Sponsor
- Alterity Therapeutics
- Start
- May 2014
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PBT2 in Alzheimer's disease (AD) and Huntington's disease (HD), sponsored by Alterity Therapeutics. Primary endpoint: Area Under the Plasma Concentration Versus Time Curve of Caffeine at 48 hours. Started May 2014; status: completed.
02
Drugs
PBT2
03
Conditions
Alzheimer's disease (AD)Huntington's disease (HD)
Beyond the preview
Go deeper on NCT02109497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02109497.